The global health landscape is a constant reminder that the work of vaccine development is never truly finished. For example, the recent Ebola (Bundibugyo virus disease) and hantavirus (Andes hantavirus) outbreaks highlight the importance of proactive vaccine development for known pathogens, to avoid considerable use of public health resources as well as avoidable deaths. Both diseases result in a significant public health burden, with case fatality rates of 30-50% with Bundibugyo virus disease and reaching 50% with Andes hantavirus. Furthermore, no approved vaccines nor effective therapeutics are available for either Bundibugyo virus disease or Andes hantavirus, despite being first detected in 2007 and 1995, respectively.
Relevance to the North American context
Although outbreaks of both these diseases are relatively uncommon and localized, they demonstrate how migratory movement, international travel, and a lack of readiness increase the risk that infectious diseases will spread. Similarly, in North America, we face ongoing public health challenges related to infectious diseases that cross land borders, spread through communities, and create significant burden.
Examples without an approved vaccine include norovirus, and others such as influenza and COVID-19 are moving targets, requiring a continuous cycle of research to ensure vaccines remain effective against the latest strains. In addition, the aging North American population adds urgency to addressing illnesses that disproportionally impact older populations such as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections.
These examples show that scientific discovery is the first step in a longer process to bring a vaccine to the public. Proactive, high-quality clinical research is a key part of public health preparedness and involves many operational steps.
Approaches to vaccine clinical trials
Successful vaccine trials are supported by well-planned and executed strategies, with key elements including the following:
- Targeted and diverse recruitment: Successful trials depend on proactive community outreach to build relationships with diverse populations. A vaccine's effectiveness must be demonstrated across a representative sample of the population it is intended to protect, including various ages, ethnicities, and individuals with different health statuses. This requires a deep understanding of community dynamics and a commitment to making participation accessible.
- Building a foundation of trust: Building public trust is fundamental to any successful vaccination program, and that trust begins during the clinical trial. It is earned through clear communication, thorough informed consent, transparent processes, and respect for participants' time and contributions. When participants feel valued and informed, they become partners in the research, which leads to higher retention rates and more reliable data.
- Operational consistency and data quality: In vaccine trials, operational consistency is essential. This includes everything from meticulous record-keeping and sample handling to standardized procedures for all staff members. Ensuring high-quality data is paramount, as this information forms the basis for regulatory approval and public health recommendations.
The role of a clinical trial site network
Implementing these strategies consistently across multiple locations is a major logistical challenge. An integrated site network is more than just a collection of research centers; it is a coordinated infrastructure that can effectively manage the complexities of vaccine development, offering the following key benefits:
- Accelerating timelines with established reach: An established network with locations in different communities provides immediate access to a broad and varied patient population. This can significantly speed up recruitment, a common delay in vaccine development. Rather than starting from scratch for each trial, a network can utilize its existing community connections and patient databases to get studies underway more efficiently.
- Ensuring quality through centralized standards: A network helps ensure consistency by implementing standardized operating procedures (SOPs), training, and quality control across all its sites. This centralized approach means that every part of the trial is conducted with the same level of precision, to generate reliable, defensible data.
- Responding to epidemiological shifts: A geographically diverse network can be strategically agile. It allows research to follow the movement of an infectious disease, placing trials in locations where exposure is more likely. This ability to align study sites with current or anticipated disease hotspots is a significant advantage for vaccine trials, which often depend on enrolling participants in areas of active transmission.
- Sharing expertise and best practices: A network creates a collaborative environment where knowledge and best practices are shared among sites. This collective experience allows the entire organization to adapt to new challenges, refine its processes, and improve the quality of its work over time.
Strengthening public health preparedness
The work of protecting public health is a collaborative effort between scientific innovation and clinical application. A well-coordinated, patient-focused clinical trial framework is essential for conducting studies with the efficiency, diversity, and quality needed to create the bridge between a promising discovery and a deliverable, trusted vaccine.
About the author
Since founding Peninsula Research Associates (PRA) in 1999, Dr. Sher has been the PI for over 200 clinical trials for conditions such as allergic rhinitis, asthma, ADHD, COPD, hypertension, otitis media, pneumonia, and sinusitis. Many of these trials have contributed to new medications and devices in the market. Dr. Sher continues to work as a physician at Palos Verdes Medical Group, a multispecialty practice and urgent care center encompassing pediatric care; ADHD; internal medicine; and adult and pediatric asthma, allergy, and immunology. He also stays involved in the community in programs such as the Los Angeles County School Nurses Association and Food Allergy and Anaphylaxis Network, where he is currently the Medical Chair for the South Bay region. He has also been appointed to serve on several national committees for the American Academy of Allergy, Asthma, & Immunology and American College of Allergy, Asthma, and Immunology including the Specific IgE Task Force, Immunotherapy and Allergy Diagnostics Committee, and Rhinitis and Sinusitis Committee.